

Justin R Bailey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/337012/publications.pdf>

Version: 2024-02-01

42
papers

2,715
citations

218677

26
h-index

276875

41
g-index

46
all docs

46
docs citations

46
times ranked

3204
citing authors

#	ARTICLE	IF	CITATIONS
1	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , 2022, 162, 562-574.	1.3	20
2	A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1253-1260.	4.7	73
3	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. <i>PLoS Pathogens</i> , 2022, 18, e1010179.	4.7	6
4	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	5.0	23
5	A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. <i>Transplantation</i> , 2022, 106, 1440-1444.	1.0	49
6	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	5
7	Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	76
8	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. <i>Aids</i> , 2021, 35, 2399-2401.	2.2	76
9	Mechanisms of HCV resistance to broadly neutralizing antibodies. <i>Current Opinion in Virology</i> , 2021, 50, 23-29.	5.4	5
10	Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication. <i>Aids</i> , 2021, Publish Ahead of Print, .	2.2	1
11	Decreased Activated CD4 ⁺ T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 ⁺ T Cell Recovery. <i>Viral Immunology</i> , 2021, 34, 622-631.	1.3	2
12	Broadly neutralizing antibodies against hepatitis C virus: location, location, location. <i>Journal of Hepatology</i> , 2020, 72, 604-606.	3.7	4
13	An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. <i>ELife</i> , 2020, 9, .	6.0	21
14	Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. <i>Journal of Virology</i> , 2019, 93, .	3.4	37
15	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. <i>Gastroenterology</i> , 2019, 156, 418-430.	1.3	162
16	Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). <i>Methods in Molecular Biology</i> , 2019, 1911, 441-450.	0.9	17
17	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. <i>Journal of Clinical Investigation</i> , 2019, 129, 4786-4796.	8.2	33
18	Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E82-E91.	7.1	52

#	ARTICLE	IF	CITATIONS
19	Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?. Trends in Microbiology, 2018, 26, 854-864.	7.7	39
20	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host and Microbe, 2018, 24, 703-716.e3.	11.0	95
21	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host and Microbe, 2018, 24, 717-730.e5.	11.0	78
22	Defining Breadth of Hepatitis C Virus Neutralization. Frontiers in Immunology, 2018, 9, 1703.	4.8	12
23	CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Science Advances, 2018, 4, eaat0843.	10.3	64
24	No recovery of replication-competent HIV-1 from human liver macrophages. Journal of Clinical Investigation, 2018, 128, 4501-4509.	8.2	41
25	Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. EBioMedicine, 2017, 16, 141-149.	6.1	27
26	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathogens, 2017, 13, e1006235.	4.7	47
27	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight, 2017, 2, .	5.0	129
28	Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology, 2016, 64, 1922-1933.	7.3	60
29	A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2016, 90, 3773-3782.	3.4	24
30	Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. Journal of General Virology, 2016, 97, 2883-2893.	2.9	27
31	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. Journal of Virology, 2015, 89, 9454-9464.	3.4	19
32	Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. Journal of Clinical Investigation, 2015, 125, 437-447.	8.2	78
33	Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology, 2014, 59, 2140-2151.	7.3	230
34	Constraints on Viral Evolution during Chronic Hepatitis C Virus Infection Arising from a Common-Source Exposure. Journal of Virology, 2012, 86, 12582-12590.	3.4	23
35	Evidence of CD8 ⁺ T-Cell-Mediated Selective Pressure on Human Immunodeficiency Virus Type 1 in HLA-B*57 ⁺ Elite Suppressors. Journal of Virology, 2009, 83, 88-97.	3.4	59
36	Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor. Journal of Virology, 2008, 82, 7395-7410.	3.4	90

#	ARTICLE	IF	CITATIONS
37	Evolution of HIV-1 in an HLA-B*57+ Positive Patient during Virologic Escape. Journal of Infectious Diseases, 2007, 196, 50-55.	4.0	55
38	Planning for the HPV Vaccine and Its Impact on Cervical Cancer Prevention. Comprehensive Therapy, 2006, 32, 102-105.	0.2	1
39	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 ⁺ T Cells. Journal of Virology, 2006, 80, 6441-6457.	3.4	377
40	Maintenance of viral suppression in HIV-1 infected HLA-B*57+ elite suppressors despite CTL escape mutations. Journal of Experimental Medicine, 2006, 203, 1357-1369.	8.5	250
41	Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy. Journal of Virology, 2006, 80, 4758-4770.	3.4	156
42	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Current Opinion in Immunology, 2004, 16, 470-476.	5.5	53